Acyl-CoA : cholesterol acyltransferase (ACAT) plays a key role in intestinal absorption of dietary cholesterol, incorporation of hepatic cholesterol into very low density lipoprotein (VLDL) and vascular accumulation of cholesterol in hyperlipidemia and atherosclerosis.
Acyl-CoA : cholesterol acyltransferase (ACAT) plays a key role in intestinal absorption of dietary cholesterol, incorporation of hepatic cholesterol into very low density lipoprotein (VLDL) and vascular accumulation of cholesterol in hyperlipidemia and atherosclerosis. 1) Thus, inhibition of ACAT has been believed to lower serum cholesterol level and also directly prevent deposition of cholesterol in atherosclerotic plaques. There have been a number of attempts to develop ACAT inhibitors as a novel type of anti-atherosclerotic drug, 2, 3) however, none has been successfully developed for clinical use. Most of the early ACAT inhibitors with high lipophilicity showed low oral bioavailability and had adrenal and/or hepatic toxicity. Adrenotoxicity is a critical problem for ACAT inhibitors, and early studies reported that it may be due to their nonspecific cytotoxicity rather than to ACAT inhibitory activity. 3, 4) Rapid and strong ACAT inhibition has recently been suggested to increase the intracellular free cholesterol level, which causes damage to adrenal plasma membrane.
3) It may be difficult to completely inhibit vascular and macrophage ACAT without affecting adrenal ACAT, since a recent monoclonal antibody study showed that adrenal and vascular ACAT are both the same subtype, ACAT-1. 5) Bioavailable and weak ACAT inhibitors such as CI-1011 have been reported to show little adrenotoxicity. 3, 6) However, these weak ACAT inhibitors without adrenotoxicity may not effectively prevent cholesterol deposition in atherosclerotic plaques. There have been only a few reports on the effects of ACAT inhibitor on atherosclerosis in Watanabe Heritable Hyperlipidemic (WHHL) rabbits, which are a reliable genetic model of familial hyperlipidemia. E5324 significantly reduced the atherosclerotic area in WHHL rabbits, 7) while FR145237 had no significant effect on atherosclerosis in these rabbits but had adrenotoxic effects in cholesterol-fed rabbits. 8, 9) On the other hand, oxidized but not native low density lipoprotein (LDL) is taken up into macrophages in a non-regulated manner and then cholesterol is accumulated via re-esterification by ACAT. 10) Therefore, anti-oxidant therapy is effective to prevent atherosclerosis. 11) Indeed, probucol reduces atherosclerotic area and xantoma by inhibition of LDL-peroxidation without affecting blood cholesterol levels in WHHL rabbits. 12) We hypothesized that bioavailable moderate ACAT inhibitors with inhibitory effects on LDL-oxidation would be safe and effective anti-atherosclerotic drugs.
The aim of this study was synthesis of a novel effective anti-atherosclerotic drug with dual inhibitory activity against ACAT and lipid-peroxidation. Two types of ACAT inhibitors have been reported to date ( Fig. 1 ): compounds such as YM-750 and RP64477 with a urea or amide structure incorporated between two aromatic rings (Ar-Ar type), and those such as E5324, CI-976 and TEI-6522 with a urea or amide structure incorporated between an aromatic ring and an aliphatic chain (Ar-Al type). 1, [13] [14] [15] [16] Most of the known ACAT inhibitors are very potent but show poor oral bioavailability probably due to their high lipophilicity and/or high molecular weight. An indoline structure was reported to act as a pharmacophore responsible for the inhibitory effect of indapamide on lipid-peroxidation. 17, 18) We synthesized a series of indoline derivatives with an amide or urea moiety to find an effective anti-atherosclerotic drug with inhibitory effects on ACAT and lipid-peroxidation, and to determine whether the indoline structure is a useful pharmacophore in the molecular design of anti-peroxidative drugs.
Chemistry As shown in Chart 1, indole derivatives 1, i.e. 6-methylindole 19) February 28, 2000 prepared according to the previously described methods. 1-Acetylindoline derivatives 2a-2e were obtained from corresponding indole derivatives 1a-1e by reduction with sodium cyanoborohydride in AcOH followed by acetylation with Ac 2 O. 1-Acetylindoline derivatives 2a-2e were brominated to give 1-acetyl-5-bromoindoline derivatives 3a-3e, which were nitrated with fuming nitric acid in H 2 SO 4 and AcOH to give 1-acetyl-5-bromo-7-nitroindoline derivatives 24) 4a-4e. Removal of the acetyl group of 4a-4e was performed using NaOH, and the resulting indolines were alkylated by treatment with NaH and alkyl iodide in N,N-dimethylformamide (DMF) to afford 1-alkyl-5-bromo-7-nitroindoline derivatives 5a-5e. Catalytic reduction of 5a-5e using 5% Pd-C gave corresponding 1-alkyl-7-aminoindoline derivatives, which were condensed with the appropriate isocyanate or acyl chloride, then deprotected if necessary, to afford the indoline derivatives (20-25, 27, 32-48, 58-61). 1-Acetyl-5-bromo-4,6-dimethyl-7-nitroindoline (4c) was reduced using 5% Pd-C to give 1-acetyl-7-amino-4,6-dimethylindoline, which was condensed with pivaloyl chloride to afford 6c followed by hydrolysis of its acetyl group and condensation with the appropriate bromide, then deprotected if necessary to give the indoline derivatives (49-57, 62-66).
As shown in Chart 2, nitration of indoline derivatives (2a, 2c) with fuming nitric acid in Ac 2 O gave 1-acetyl-5-nitroindoline derivatives (7a, 7c), then hydrolysis of 7a and 7c provided 5-nitroindoline derivatives (8a, 8c), which were alkylated by treatment with NaH and hexyliodide in DMF to afford 1-hexyl-5-nitroindoline derivatives (9a, 9c). Catalytic reduction of 9a and 9c using 5% Pd-C gave the corresponding amines which were condensed with the appropriate isocyanate or pivaloyl chloride to afford the indoline derivatives (19, 26, 30) .
As shown in Chart 3, 5,7-dimethylindole (11) was synthesized from 2,4-dimethylaniline (10) according to the procedure described by Demerson et al. 22) Compound 11 was reduced with sodium cyanoborohydride in AcOH and nitrated with fuming nitric acid in H 2 SO 4 25) to give 5,7-dimethyl-6-nitroindoline (13), which was alkylated by treatment with NaH and hexyl iodide in DMF to afford 1-hexyl-5,7-dimethyl-6-nitroindoline (14) . Catalytic reduction of 14 using 5% Pd-C gave the corresponding amine, which was condensed with pivaloyl chloride to afford the indoline derivative 28.
As shown in Chart 4, 1-acetyl-5-hydroxyindoline 26) (15) was alkylated by treatment with K 2 CO 3 and alkyl bromide in EtOH to afford 1-acetyl-5-alkyloxyindolines (16a, 16b), which were nitrated with fuming nitric acid in Ac 2 O to give 1-acety-5-alkyloxy-6-nitroindoline derivatives 17a and 17b. Removal of the acetyl groups of 17a and 17b was performed using HCl, and the resulting indolines were alkylated by treatment with K 2 CO 3 and alkyl iodide in DMF to afford 1-alkyl-5-alkyloxy-6-nitroindoline derivatives (18a, 18b). Catalytic reduction of 18a and 18b using 5% Pd-C gave the corresponding 1-alkyl-6-aminoindoline derivatives, which were condensed with pivaloyl chloride to afford the indoline derivatives (29, 31).
Results and Discussion
We designed and synthesized a series of Ar-Ar type urea derivatives and Ar-Al type urea and amide derivatives based on the indoline structure, the molecular weights of which were limited to around 400, and examined their in vitro activity against rabbit intestinal ACAT and lipid-peroxidation of rat brain homogenate.
In the first set of experiments, indoline derivatives with a substituted urea moiety were synthesized, and the biological results are shown in Table 1 . Compound 19 with 2,4,6-trimethylphenyl urea at the 5-position and a hexyl group at the 1-position had little effect on ACAT. Compound 20, an isomer of 19, with the same urea moiety at the 7-position had weak ACAT inhibitory activity. Furthermore, decreases in size of the 1-alkyl chain resulted in reduction of the activity (20 vs. 21) . Compounds 23 and 24 with 2-(hexyloxy)phenyl urea showed relatively potent ACAT inhibition, while compound 25 with 4-(hexyloxy)phenyl urea, which is an isomer of 23, showed lower activity. Compound 26 with n-butylurea at the 5-position and a hexyl group at the 1-position was about 3-fold weaker than that of its 7-positional isomer 27. These results demonstrated that introduction of a lipophilic and bulky substituent(s) into a position close to the urea moiety enhanced the inhibitory effect on ACAT activity. In a series of N-(substituted phenyl)ureas, the introduction of bulky substituents isopropyl and ethyl into the ortho-position has been reported to markedly increase the activity against ACAT.
27) The compounds listed in Table 1 showed inhibitory effects on lipid-peroxidation comparable to or greater than that of probucol, indicating that introduction of an indoline structure could confer anti-peroxidative activity. The most potent compound, 24, showed about 18-fold weaker ACATinhibitory activity than that of YM-750 and more potent antiperoxidative activity than that of probucol.
In the next set of experiments, we attempted to design Ar-Al type indolinyl amide derivatives to find a lead compound smaller than 24 (M.W. 451.6). Known typical Ar-Al type ACAT inhibitors such as CI-976 and TEI-6522 have a long alkyl amide chain. 15, 16) However, of the TEI-6522 derivatives (oxochroman derivatives), a compound with 2,2-dimethylpropanamide combined with the ortho-decyloxy group showed a relatively strong inhibitory activity against ACAT.
16) Thus, we synthesized indoline derivatives with a small alkylamide moiety and a hexyl or hexyloxy chain. The chemical structures and results are shown in Table 2 . Compounds 28-30 with an amide moiety at the 5-or 6-position and a hexyl group at the 1-position showed weak ACAT inhibitory activity. The activity of 31 with an amide moiety at the 6-position and a hexyloxy group at the 5-position was relatively high compared with 28-30. A bulky and lipophilic substituent (hexyloxy) flanking the amide moiety enhanced the ACAT inhibitory activity as shown in the urea derivatives (Table 1) . Among 32-36 with an amide moiety at the 7-position, 32-35 showed moderate ACAT inhibitory activity and 36 relatively weak activity. These results implied that methyl, methoxy or ethyl substituents at the 4-and/or 6-position (33-36) did not increase the activity. In fatty acid anilide derivatives including CI-976, the substituents methyl, methoxy, ethyl or isopropyl at the ortho-position of alkylamide effectively increased the ACAT inhibitory activity. 15) Unlike CI-976, our system had a bicyclic structure (indoline) and a bulky moiety at the 1-position on the ring. Thus, additional substituents at 4-and 6-positions may have failed to further increase the activity. Interestingly, despite the similar in vitro activity, compound 34 showed a markedly more potent in vivo anti-hyperlipidemic effect than 32, 33, 35 and 36. When administered orally to rats fed a high-cholesterol diet, compounds 32-36 lowered serum cholesterol levels by 14.1% at 10 mg/kg, 11.7% at 30 mg/kg, 42.0% at 10 mg/kg, 19.2% at 30 mg/kg and 4.0% at 10 mg/kg, respectively. These differences of in vivo activity may have been attributable to absorption and/or metabolic resistance of the compounds. The compounds listed in Table 2 all showed more potent anti-peroxidative activity than probucol. Compound 34 was then chosen as a lead compound for structural optimization to enhance the inhibitory activity on ACAT.
Derivatives of 34 with various substituents at the 1-position (R 1 ) and at the terminal of the amide (R 7 ) were synthesized (Table 3) . Of the 1-hexyl derivatives, compound 37 was a weaker ACAT inhibitor than 34, but 38-43 were roughly equipotent to 34, indicating that the ACAT inhibitory activity is not highly dependent on size of R 7 . In other Ar-Al type ACAT inhibitors such as CI-976 and TEI-6522, ACAT inhibitory activity is closely related to the length of the alkyl 820 Vol. 48, No. 6 amide chain. 15, 16) In compounds 34 and 37-43, the 1-hexyl chain but not alkylamide moiety appeared to be important for interaction with the hydrophobic region of the enzyme. ACAT is considered to have one large hydrophobic interaction area, and thus only one lipophilic group in the ACAT inhibitor can interact with the enzyme, as previously described in a series of oxochroman derivatives which also have a long alkyl chain near the alkylamide moiety. 16) In compounds 44-46 with an ethyl instead of a hexyl group at the 1-position, ACAT inhibitory activity was moderately related to the carbon number of R 7 . Increase of the carbon number by 8 at R 7 resulted in only 8-fold enhancement of ACAT inhibitory activity (44 vs. 46). In contrast, comparison among 44, 47-57 with 2,2-dimethylpropanamide at the 7-position demonstrated that the ACAT inhibitory activity was notably dependent on carbon number of the alkyl moiety at the 1-position (R 1 ). Increase of the carbon number by 8 at R 1 resulted in 43-fold enhancement of the ACAT inhibitory activity (44 vs. 56). These results clearly demonstrated that the 1-alkyl moiety interacted more effectively with ACAT than the alkyl amide moiety in the indoline derivatives. With respect to length of R 1 , the activity appeared to reach the maximal level in octyl (55), since 55-57 showed similar IC 50 values. Comparison among 48-51, between 34 and 52 and between 53 and 54 showed that introduction of a branched, cyclic structure, or a double bond into the 1-alkyl moiety tended to decrease ACAT inhibitory activity. The indoline structure with 2,2-dimethylpropanamide and 1-long alkyl chain was identified as a new system favorable for ACAT inhibition. All compounds listed in Table 3 showed anti-peroxidative activity greater than that of probucol.
To decrease the lipophilicity of compound 55 which showed 5-fold weaker ACAT inhibitory activity than YM-750 and more potent anti-peroxidative activity than probucol, we introduced the polar groups hydroxy, amine, carboxylic acid or basic heterocycles into R 1 or R 7 (Table 4 ). However, R 1 or R 7 bearing polar groups reduced ACAT inhibitory activity in 58-66. Basic but not acidic groups have been successfully introduced into some ACAT inhibitors. 14, 28, 29) In compounds 59 and 62, anti-peroxidative activity was also markedly reduced.
Finally, we selected compound 55 for further evaluation and the results are shown in Table 5 . This compound was about 2-fold weaker than YM-750 against hepatic ACAT and about 3-fold safer with regard to hepatic/adrenal ACAT selectivity. Compound 55 and YM-750 lowered serum cholesterol levels to similar degrees not only in hyperlipidemic rats fed a high cholesterol diet but also in normolipidemic hamsters fed a regular diet, suggesting the contribution of hepatic and intestinal ACAT inhibitory activity. Compound 55, but not YM-750, showed an inhibitory effect on LDL-oxidation comparable to that of probucol. The peak plasma concentration of 55 in dogs after oral administration at 10 mg/kg was 716 ng/ml, which is an effective concentration against hepatic ACAT and LDL-peroxidation. These observations indicated that compound 55 is a bioavailable ACAT inhibitor with antilipidperoxidative activity. In future studies, direct anti-atherosclerotic effects of these dual actions and adreno-safety will be determined using reliable hyperlipidemic and atherosclerotic models such as WHHL rabbits.
Conclusions
A novel series of indolinyl amide and urea derivatives were synthesized to find a new ACAT inhibitor with antilipid-peroxidative activity. Among the compounds synthesized, N-(4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide hydrochloride (55) showed moderate ACAT inhibitory activity compared to YM-750, potent anti-peroxidative activity comparable to probucol and oral bioavailability sufficient for both effects. Thus, 55 is a promising anti-atherosclerotic drug. The indoline structure was shown to be a pharmacophore responsible for anti-peroxidative activity and to be useful for molecular design of anti-peroxidative drugs.
Experimental
Melting points were measured on a Yamato capillary melting-point apparatus and are uncorrected. IR spectra were taken with a JASCO IR-800 spectrometer. 1 H-NMR spectra were recorded at 90 MHz on a Hitachi R-1900 spectrometer using tetramethylsilane as an internal standard. For column chromatography, silica gel (Daisogel No.1001W, Daiso) was used.
N-Acetyl-4,6-dimethylindoline (2c) To a solution of 4,6-dimethylindole 1c (16.0 g) in AcOH (80 ml) was added sodium cyanoborohydride (13.8 g) portionwise at 5°C. The reaction mixture was stirred at the same temperature for 1 h, then was poured into ice water and neutralized with 5 N aq. NaOH. 4,6-Dimethylindoline was extracted with AcOEt (200 ml) and the extracts were washed with water and dried. The solvent was removed in vacuo to give 4,6-dimethylindoline as an oil which was used for the next reaction without purification. To the solution of 4,6-dimethylindoline in CHCl 3 (100 ml) was added Ac 2 O (13.5 g) followed by stirring at 20°C for 1 h. The reaction mixture was washed with aq. NaHCO 3 and dried. The solvent was removed in vacuo to afford a solid, which was purified by column chromatography (benzene-AcOEt) to yield 2c (19 . N-Acetyl-5-bromo-4,6-dimethyl-7-nitroindoline (4c) To a stirred solution of 2c (5.5 g) in AcOH (110 ml), Br 2 (2.0 ml) was added dropwise. The reaction mixture was stirred for a few minutes and then was poured into ice water. The suspension was treated with sodium bisulfite to remove the excess Br 2 , and the solid was collected and recrystallized from MeOH to give 3c as white crystals (6.5 g, yield 83%). mp 170-172°C. 1 . 3c (6.5 g) was added portionwise to a mixture of fuming nitric acid (1.4 ml), AcOH (25 ml) and H 2 SO 4 (25 ml) at 5°C. The reaction mixture was stirred at the same temperature for 6 h, and then poured into ice water. The precipitate was collected and washed with water to give 4c (7.0 g, yield 93%). N-Hexyl-5-bromo-4,6-dimethyl-7-nitroindoline (5c) A solution of 4c (5.0 g) and NaOH (3.2 g) in 80% MeOH (50 ml) was refluxed for 2 h. After removal of the solvent in vacuo, the residue was diluted with CHCl 3 . The solution was washed with water and dried. The solvent was removed in vacuo to give a solid, which was purified by column chromatography (hexane) to give 5-bromo-4,6-dimethyl-7-nitroindoline (3.0 g, yield 69% . To a solution of 5-bromo-4,6-dimethyl-7-nitroindoline (3.0 g) in dry DMF (50 ml) was added NaH (ca. 60%, 530 mg) followed by stirring at 20°C for 0.5 h. To the reaction mixture was added n-hexyl iodide (2.5 g) and the whole was stirred for 10 h at the same temperature. It was then poured into ice water and 5c was extracted with AcOEt (100 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to yield 5c as an oil (3.1 g, yield 79%). N-(1-Hexyl-4,6-dimethylindolin-7-yl)-N-butylurea (27) A solution of 5c (2.0 g) in benzene (50 ml) was hydrogenated at 3 atm in the presence of 5% Pd-C (500 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. The residue was diluted with CHCl 3 (50 ml) and the solution was washed with aq. NaHCO 3 and dried. To the solution was added n-butyl isocyanate (550 mg) and the mixture was stirred at 20°C under N 2 for 20 h. The reaction mixture was concentrated in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 27 as a solid (850 mg, yield 42% The following compounds 20-25 were prepared in a manner similar to that described for 27 from N-hexyl-5-bromo-7-nitroindoline (5a) and the appropriate isocyanate. . (23) . (24) . (25) N-(1-Hexyl-4,6 -dimethylindolin-7-yl)-2,2-dimethylpropanamide Hydrochloride (34) A solution of 5c (2.0 g) in benzene (50 ml) was hydrogenated at 3 atm in the presence of 5% Pd-C (500 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. The residue was diluted with CHCl 3 (50 ml) and the solution was washed with aq. NaHCO 3 and dried. To the solution were added pivaloyl chloride (670 mg) and triethylamine (620 mg) followed by stirring at 20°C for 1 h. The reaction mixture was washed with 5% aq. citric acid, water and dried. The solvent was removed in vacuo. The residue was purified by column chromatography (CHCl 3 -MeOH) to give an oil, which was converted to HCl salt and was recrystallized from EtOH to give 34 (700 mg, yield 34% . Acetyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (6c) A suspension of 4c (10 g) in MeOH (300 ml) was hydrogenated at 3 atm in the presence of 5% Pd-C (500 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. The residue was diluted with CHCl 3 (200 ml) and the solution was washed with aq. NaHCO 3 and dried. To this solution were added pivaloyl chloride (3.9 g) and triethylamine (3.2 g) followed by stirring at 20°C for 1 h. The reaction mixture was washed with 5% aq. citric acid, water and dried. The solvent was removed in vacuo to give a solid, which was purified by column chromatography (CHCl 3 -MeOH) to give 6c (6.6 g, yield 71%). . N-(4,6-Dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide Hydrochloride (55) A solution of 6c (3.7 g) and NaOH (2.6 g) in 60% MeOH (20 ml) was refluxed for 7 h. After removal of the solvent in vacuo, the residue was diluted with CHCl 3 (100 ml), washed with water and dried. The solvent was removed in vacuo to give N-(4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (2.1 g, yield 65% ), which was used for the following reaction without further purification. A mixture of N-(4,6-dimethylindolin-7 yl)-2,2-dimethylpropanamide (2.1 g), n-octyl bromide (4.1 g) and K 2 CO 3 (2.3 g) in DMF (30 ml) was stirred under N 2 at 40°C for 10 h. The reaction mixture was poured into water and extracted with AcOEt (100 ml). The extracts were washed with water and dried. The solvent was removed in vacuo. The residue was purified by column chromatography (CHCl 3 -MeOH) to give an oil, which was converted to HCl salt and was recrystallized from EtOH to give 55 (2.0 g, yield 59%). mp 123-124°C.
N-(1-Hexylindolin-7-yl)-NЈ-(2,4,6-trimethylphenyl)urea

N-(1-Ethylindolin-7-yl)-N Ј-(2-hexyloxy-4-methylphenyl)urea
N-(1-Hexylindolin-7-yl)-NЈ-(2-hexyloxy-4-methylphenyl)urea
N-(1-Ethylindolin-7-yl)-N Ј-(4-hexyloxy-2-methylphenyl)urea
N-(1-Hexyl-4,6-dimethoxyindolin-7-yl)-2,2-dimethylpropanamide
N-(1-
1 H-NMR (CDCl 3 ) d: 0. 87 (br t, 3H), 1.1-1.9 (m, 12H), 1.42 (s, 9H), 2.16 (s, 3H), 2.26 (s, 3H),  2.9-3.3 (m, 4H), 3.5-4.2 (m, 2H), 7.11 (s, 1H), 9.21 (br, 1H) . IR (Nujol): 3200, 1660, 1625 cm The following compounds 49-57 and 62-66 were prepared in a manner similar to that described in 55 from 6c and the corresponding halide. . A solution of 7c (2.4 g) and conc. HCl 10 ml in MeOH (100 ml) was refluxed for 10 h. After removal of the solvent in vacuo, the residue was diluted with CHCl 3 (200 ml). The solution was washed with water, aq. NaHCO 3 and dried. The solvent was removed in vacuo to give an oil which was purified by column chromatography (hexane) to give 8c as a solid (1.8 g, yield 99% . To a solution of 8c (1.8 g) in dry DMF (20 ml) was added NaH (ca. 60%, 450 mg) followed by stirring at 20°C for 0.5 h. To the reaction mixture was added n-hexyl bromide (1.8 g) followed by stirring at the same temperature for 5 h. The mixture was then poured into ice water and 9c was extracted with AcOEt (300 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to give 9c as an oil (2.5 g, yield 88%). (25 ml ) was hydrogenated at 3 atm in the presence of 5% Pd-C (250 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. To the residue dissolved in CHCl 3 (20 ml) was added n-butyl isocyanate (400 mg) followed by stirring under N 2 at 20°C for 20 h. The reaction mixture was washed with water and dried. The solvent was removed in vacuo to give a solid, which was purified by column chromatography (CHCl 3 -MeOH) and was recrystallized from EtOH to give 26 (650 mg, yield 52%). mp 143-145°C. 1 A solution of 9c (1.0 g) in benzene (25 ml) was hydrogenated at 3 atm in the presence of 5% Pd-C (250 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. To the residue dissolved in CHCl 3 (20 ml) was added pivaloyl chloride (470 mg) and triethylamine (395 mg) followed by stirring at 20°C for 1 h. The reaction mixture was washed with 5% aq. citric acid, water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) and was recrystallized from EtOH to give 30 (900 mg, yield 76%). mp 122-123°C. 1 . 5,7-Dimethyl-6-nitroindoline (13) To a solution of 5,7-dimethylindole 11 (3.4 g) in AcOH (340 ml) was added sodium cyanoborohydride (2.9 g) at 10°C, and the reaction mixture was stirred at the same temperature for 1 h. The mixture was poured into ice water and neutralized with 5 N aq. NaOH. 5,7-Dimethylindoline 12 was extracted with AcOEt (200 ml). The extracts were washed with water and dried and the solvent was removed in vacuo to give 12 as an oil (2.5 g, yield 73% . Fuming nitric acid (0.78 ml) in H 2 SO 4 (5 ml) was added dropwise to a solution of 12 (2.5 g) in H 2 SO 4 (25 ml) at 5°C. After stirring at the same temperature for 1 h, the reaction mixture was poured into water and neutralized with aq. NaOH, and 13 was extracted with CHCl 3 (100 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 13 as an oil (2.3 g, yield 70%). N-(1-Hexyl-5,7-dimethylindolin-6-yl)-2,2-dimethylpropanamide (28) To a solution of 13 (2.3 g) in dry DMF (23 ml) was added NaH (ca. 60%, 530 mg), and the mixture was stirred at 20°C for 0.5 h. To the reaction mixture was added n-hexyl iodide (2.8 g) followed by stirring at the same temperature for 15 h. The mixture was poured into ice water and 14 was extracted with AcOEt (100 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to give 14 as an oil (1.0 g, yield 30% A solution of 14 (1.0 g) in benzene (40 ml) was hydrogenated at 3 atm in the presence of 5% Pd-C (250 mg) at 30°C for 10 h. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo. To the residue dissolved in CHCl 3 (20 ml) were added pivaloyl chloride (470 mg) and triethylamine (400 mg) followed by stirring at 20°C for 1 h. The reaction mixture was washed with 5% aq. citric acid, water and dried. The solvent was removed in vacuo to give an oil which was purified by column chromatography (CHCl 3 -MeOH) and was recrystallized from EtOH to give 28 (100 mg, yield 8.4%). mp 117-118°C. . N-Acetyl-5-hexyloxy-6-nitroindoline (17a) The mixture of N-acetyl-5-hydroxyindoline 15 (5.0 g), n-hexyl bromide (5.6 g) and K 2 CO 3 (8.0 g) in EtOH (50 ml) was refluxed for 10 h. After removal of EtOH in vacuo, the residue was diluted with AcOEt (100 ml). The solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to give 16a as a solid (5.2 g, yield 58%). Fuming nitric acid (0.99 ml) was added dropwise to the solution of 16a (5.2 g) in Ac 2 O (52 ml) at 5°C. After stirring at 20°C for 1 h, the reaction mixture was neutralized with aq. NaHCO 3 and 17a was extracted with CHCl 3 (200 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give 17a as a solid (2.9 g, yield 47%). . N-(1-Ethyl-5-hexyloxyindolin-6-yl)-2,2-dimethylpropanamide Hydrochloride (31) A solution of 17a (2.0 g) and conc. HCl (6 ml) in MeOH (40 ml) was refluxed for 4 h. After removal of the MeOH in vacuo, the residue was neutralized with aq. NaHCO 3 . 5-Hexyloxy-6-nitroindoline was extracted with AcOEt (100 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (hexane) to give 5-hexyloxy-6-nitroindoline as an oil (1.6 g, yield 92%). The mixture of 5-hexyloxy-6-nitroindoline (1.6 g), ethyl iodide (1.0 g) and K 2 CO 3 (1.7 g) in dry DMF (16 ml) was stirred at 20°C for 10 h. The reaction mixture was poured into ice water, and 18a was extracted with AcOEt (200 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to give 18a as oil (1.3 g, yield 73% ).
1 H-NMR (CDCl 3 ) d: 0.90 (br t, 3H), 1.18 (t, 3H, Jϭ7.2 Hz), 1.1-1.9 (m, 8H), 2.97 (t,
